Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price traded down 25% during trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03. 123,238 shares changed hands during mid-day trading, an increase of 414% from the average session volume of 23,982 shares. The stock had previously closed at C$0.04.
Quest PharmaTech Trading Down 25.0%
The firm’s 50-day simple moving average is C$0.04 and its 200-day simple moving average is C$0.04. The firm has a market capitalization of C$5.07 million, a PE ratio of -30.00 and a beta of 0.00. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Stories
- Five stocks we like better than Quest PharmaTech
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
